| Budget Amount *help |
¥19,240,000 (Direct Cost: ¥14,800,000、Indirect Cost: ¥4,440,000)
Fiscal Year 2010: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2009: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
Fiscal Year 2008: ¥7,150,000 (Direct Cost: ¥5,500,000、Indirect Cost: ¥1,650,000)
|
|---|
| Research Abstract |
Excess activation or differentiation of born-resorbing osteoclasts results in exacerbation of osteoporosis and rheumatoid arthritis. To develop bone-resorption depressants, we analyzed osteoclastogenic signals and found that HCR (Highly Conserved domain in RANK) of the RANK receptor is crucial for differentiation of osteoclasts. We also identified the HCR-binding proteins that may function together with HCR to promote osteoclastogenesis. Moreover, we have already begun to search compounds that could be used as bone-resorption depressants by inhibiting osteoclastogenic signals through HCR using the chemical compound library.
|
